drugset / Trial / NCT01685931

A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics

NCT01685931

Phase 4 Completed 617 enrolled Xian-Janssen Pharmaceutical Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the effectiveness, safety and tolerability of flexibly dosed paliperidone palmitate in patients with schizophrenia previously unsuccessfully treated by oral antipsychotics and with acute symptom of schizophrenia.

Timeline

Start
2012-11
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject paliperidone palmitate Unknown Intramuscular

Indications